Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming Frances Fitzgerald .
Filed returns
9
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2022 | Pfizer | EU Affairs | European System of Accounts (EU Accounting Rules) (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Science Foundation Ireland has a research centre, INNATE which has been approved in principle but requires funding. The infrastructure and focus intended by INNATE would help upskill scientists and help translate early… (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant burden for five of Pfizer's Irish… (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Economic Development and Industry | Global competition for foreign direct investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant administrative and cost burden for five… (Legislation) | 11 | On lobbying.ie |
| May–Aug 2016 | Pfizer | Health | raise awareness of metastatic breast cancer which is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if diagnosed early, 30% of women diagnosed with early breast… (Public policy or programme) | 4 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 5 | 55.6% | |
| Economic Development and Industry | 3 | 33.3% | |
| EU Affairs | 1 | 11.1% |